Disease trajectories and mortality among women diagnosed with breast cancer

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66(1):31–42.

Brand JS, Colzani E, Johansson ALV, Giesecke J, Clements M, Bergh J, Hall P, Czene K. Infection-related hospitalizations in breast cancer patients: risk and impact on prognosis. J Infect. 2016;72(6):650–8.

Hemminki K, Liu X, Ji J, Forsti A, Sundquist J, Sundquist K. Effect of autoimmune diseases on risk and survival in female cancers. Gynecol Oncol. 2012;127(1):180–5.

Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011;20(2):131–7.

Edwards BK, Noone AM, Mariotto AB, Simard EP, Boscoe FP, Henley SJ, Jemal A, Cho H, Anderson RN, Kohler BA, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–314.

Danese MD, O'Malley C, Lindquist K, Gleeson M, Griffiths RI. An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol. 2012;23(7):1756–65.

Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki K. Death causes in breast cancer patients. Ann Oncol. 2012;23(3):604–10.

Lash TL, Thwin SS, Yood MU, Geiger AM, Bosco J, Quinn VP, Field TS, Pawloski PA, Silliman RA. Comprehensive evaluation of the incidence of late effects in five-year survivors of breast cancer. Breast Cancer Res Treat. 2014;144(3):643–63.

Jensen AB, Moseley PL, Oprea TI, Ellesøe SG, Eriksson R, Schmock H, Jensen PB, Jensen LJ, Brunak S. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun. 2014;5:4022.

Giannoula A, Gutierrez-Sacristán A, Bravo Á, Sanz F, Furlong LI. Identifying temporal patterns in patient disease trajectories using dynamic time warping: a population-based study. Sci Rep. 2018;8(1):4216.

Garne JP, Aspegren K, Moller T. Validity of breast-cancer registration from one hospital into the Swedish National Cancer Registry 1971-1991. Acta Oncol. 1995;34(2):153–6.

Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C, Heurgren M, Olausson PO. External review and validation of the Swedish national inpatient registry. BMC Public Health. 2011;11:450.

Brooke HL, Talbäck M, Hörnblad J, Johansson LA, Ludvigsson JF, Druid H, Feychting M, Ljung R. The Swedish cause of death registry. Eur J Epidemiol. 2017;32(9):765–73.

Johansson LA, Björkenstam C, Westerling R. Unexplained differences between hospital and mortality data indicated mistakes in death certification: an investigation of 1,094 deaths in Sweden during 1995. J Clin Epidemiol. 2009;62(11):1202–9.

Brand JS, Hedayati E, Bhoo-Pathy N, Bergh J, Hall P, Humphreys K, Ludvigsson JF, Czene K. Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: a population-based cohort study. Cancer. 2017;123(3):468–75.

Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A, Brewster DH, Pukkala E, McBride ML, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118(9):2285–92.

Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol. 2007;25(25):3808–15.

Amir O, Kishon-Rabin L. Association between birth control pills and voice quality. Laryngoscope. 2004;114(6):1021–6.

Mourits MJ, De Vries EG, Willemse PH, Ten Hoor KA, Hollema H, Van der Zee AG. Tamoxifen treatment and gynecologic side effects: a review. Obstet Gynecol. 2001;97(5 Pt 2):855–66.

Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer. 2001;93(2):155–61.

Hooning MJ, Aleman BMP, van Rosmalen AJM, Kuenen MA, Klijn JGM, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiation Oncol Biol Physics. 2006;64(4):1081–91.

Prochazka M, Hall P, Granath F, Czene K. Family history of breast cancer and young age at diagnosis of breast cancer increase risk of second primary malignancies in women: a population-based cohort study. Br J Cancer. 2006;95(9):1291–5.

Prochazka M, Hall P, Gagliardi G, Granath F, Nilsson BN, Shields PG, Tennis M, Czene K. Ionizing radiation and tobacco use increases the risk of a subsequent lung carcinoma in women with breast cancer: case-only design. J Clin Oncol. 2005;23(30):7467–74.

Burbos N, Musonda P, Giarenis I, Shiner AM, Giamougiannis P, Morris EP, Nieto JJ. Predicting the risk of endometrial cancer in postmenopausal women presenting with vaginal bleeding: the Norwich DEFAB risk assessment tool. Br J Cancer. 2010;102(8):1201–6.

Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst. 2006;98(16):1108–17.

Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med. 2001;344(26):1997–2008.

Yang H, Brand JS, Fang F, Chiesa F, Johansson AL, Hall P, Czene K. Time-dependent risk of depression, anxiety, and stress-related disorders in patients with invasive and in situ breast cancer. Int J Cancer. 2017;140(4):841–52.

Sibaud V, Lebœuf NR, Roche H, Belum VR, Gladieff L, Deslandres M, Montastruc M, Eche A, Vigarios E, Dalenc F, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016;26(5):427–43.

Shushan A, Peretz T, Uziely B, Lewin A, Mor-Yosef S. Ovarian cysts in premenopausal and postmenopausal tamoxifen-treated women with breast cancer. Am J Obstet Gynecol. 1996;174(1 Pt 1):141–4.

Nasu K, Takai N, Nishida M, Narahara H. Tumorigenic effects of tamoxifen on the female genital tract. Clin Med Pathol. 2008;1:17–34.

Palmer E, Henrikson B, McKusick K, Strauss HW, Hochberg F. Pain as an indicator of bone metastasis. Acta Radiologica (Stockholm, Sweden : 1987). 1988;29(4):445–9.

Stany MP, Farley JH. Complications of gynecologic surgery. Surg Clin N Am. 2008;88(2):343–59.

Early Breast Cancer Trialists’ Collaborative G. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451–67.

Chlebowski RT, Schottinger JE, Shi J, Chung J, Haque R. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. Cancer. 2015;121(13):2147–55.